← Theravance Biopharma, Inc.
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $48.6m |
$15.4m
-68.37%
|
$60.4m
+292.37%
|
$73.4m
+21.61%
|
$71.9m
-2.12%
|
$55.3m
-23.03%
|
$51.3m
-7.17%
|
$57.4m
+11.84%
|
$64.4m
+12.12%
|
$107.5m
+66.92%
|
$109.8m
+2.15%
|
|
| Cost of Goods and Services Sold | $2.9m |
$6.0m
+108.36%
|
$202.1m
+3250.96%
|
$219.2m
+8.50%
|
$261.0m
+19.02%
|
$213.8m
-18.07%
|
$76.2m
-64.35%
|
$43.4m
-43.11%
|
$42.2m
-2.79%
|
$37.4m
-11.25%
|
— | |
| Gross Profit (Calculated) (derived) | $45.8m |
$9.4m
-79.55%
|
($141.7m)
-1614.46%
|
($145.8m)
-2.92%
|
($189.1m)
-29.67%
|
($158.5m)
+16.19%
|
($24.9m)
+84.30%
|
$14.1m
+156.50%
|
$22.2m
+58.07%
|
$70.0m
+215.19%
|
— | |
| Research and Development Expense | $141.7m | $173.9m | $201.3m | $219.2m | $261.0m | $193.7m | $63.4m | $40.6m | $37.6m | $37.4m | $31.8m | |
| Selling, General and Administrative Expense | $84.5m | $95.6m | $97.1m | $106.1m | $108.7m | $99.3m | $67.1m | $70.1m | $69.2m | $73.7m | $73.0m | |
| Marketing and Advertising Expense | — | — | — | — | — | — | — | — | — | $5.1m | — | |
| Operating Expenses | $229.1m | $275.5m | $299.1m | $325.3m | $369.6m | $313.1m | $143.3m | $113.5m | $111.3m | $111.1m | $104.8m | |
| Operating Income (Loss) | ($180.5m) |
($260.1m)
-44.14%
|
($238.8m)
+8.22%
|
($251.9m)
-5.51%
|
($297.8m)
-18.20%
|
($257.8m)
+13.42%
|
($92.0m)
+64.33%
|
($56.0m)
+39.06%
|
($46.9m)
+16.21%
|
($3.6m)
+92.33%
|
$5.0m
+238.31%
|
|
| Interest Expense | $1.4m | $8.5m | $10.5m | $31.9m | $44.6m | $46.9m | $6.4m | $2.4m | — | — | $1.8m | |
| Interest Expense, Debt | — | — | $9.3m | $28.8m | $42.6m | $44.7m | $4.9m | — | — | — | $1.8m | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | ($900k) | $900k | $60k | ($100k) | ($100k) | — | |
| Other Nonoperating Income (Expense) | $1.3m | $5.0m | $12.0m | $8.4m | $2.8m | $1.1m | $8.5m | $9.1m | $4.9m | $10.2m | — | |
| Interest Expense (non-operating) | — | — | — | — | — | — | — | — | $2.5m | $2.5m | $1.8m | |
| Income (Loss) from Equity Method Investments | — | — | $11.2m | $33.7m | $68.4m | $104.0m | — | — | — | — | — | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | $180.6m | — | — | — | — | $199.6m | $92.8m | $49.3m | $44.6m | $20.9m | $136.9m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($180.6m) | ($271.7m) | ($226.1m) | ($241.7m) | ($286.5m) | ($199.6m) | ($92.8m) | ($49.3m) | ($44.6m) | $129.2m | $136.9m | |
| Current Income Tax Expense (Benefit) | $10.1m | $13.7m | ($10.6m) | ($5.2m) | ($8.5m) | ($151k) | $9k | ($2.7m) | $19.4m | $34.9m | $22.4m | |
| Income Tax Expense (Benefit) | $10.1m | $13.7m | ($10.6m) | ($5.2m) | ($8.5m) | ($151k) | $9k | $5.9m | $11.8m | $23.4m | $22.4m | |
| Net Income (Loss) Attributable to Parent | ($190.7m) |
($285.4m)
-49.69%
|
($215.5m)
+24.48%
|
($236.5m)
-9.71%
|
($278.0m)
-17.58%
|
($199.4m)
+28.27%
|
$872.1m
+537.32%
|
($55.2m)
-106.33%
|
($56.4m)
-2.22%
|
$105.9m
+287.70%
|
$114.5m
+8.16%
|
|
| Earnings Per Share, Basic | — | — | — | — | — | ($2.87) | $11.85 | ($1.00) | ($1.15) | $2.10 | $2.27 | |
| Earnings Per Share, Diluted | — | — | — | — | — | ($2.87) | $11.85 | ($1.00) | ($1.15) | $2.06 | $2.23 | |
| Income (Loss) from Continuing Operations, Per Basic Share | — | — | — | — | — | — | ($1) | ($1) | — | — | — | |
| Income (Loss) from Continuing Operations, Per Diluted Share | — | — | — | — | — | — | ($1) | ($1) | — | — | — | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | 56.5m | 62.8m | 69.5m | 73.6m | 55.3m | 48.8m | 50.3m | 50.7m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | 55.6m | 62.3m | 69.5m | 73.6m | 55.3m | 48.8m | 51.5m | 51.9m | |
| Additional Financial Items | ||||||||||||
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | ($92.8m) | ($55.2m) | — | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest | — | — | — | — | — | — | $965.0m | — | — | — | — | |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent | — | — | — | — | — | — | $965.0m | — | — | — | — |